^
Association details:
| Biomarker: | NPM1 mutation + SRSF2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + idarubicin (DNA replication inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial
Published date:
11/01/2018
Excerpt:
...study has explored the role of mutation patterns determined by NGS in older AML pts...Pts received one 7+3 course followed by 2 intermediate-dose cytarabine courses…The 49 NPM1mut pts with SRSF2 mutation and/or without adverse co-mutations (FLT3-ITDhighDNMT3A, ASXL1 and NRAS) had a median OS of 49.7 months, defining very low risk...
DOI:
10.1182/blood-2018-99-111144
Trial ID:
